Divalent Copper Compounds as Inhibitory Agents Against Influenza A ID: 2014-45

This study introduces divalent copper compounds as potent antiviral agents against drug-resistant Influenza A.

Technology Overview

This Master's thesis by Nathan Allan Gordon at Brigham Young University investigates the efficacy of divalent copper compounds, specifically NAG101 and NAG107, in inhibiting the Influenza A virus. By focusing on the S31N mutation in the M2 protein, the research highlights the potential of these compounds to overcome the high mutation rate and subsequent drug resistance encountered in current Influenza A treatments.

Key Advantages

• Significant antiviral activity, surpassing traditional treatments like amantadine
• Targets the M2 proton channel, blocking viral RNA release into host cells
• Low cytotoxicity, making them safer for use in potential treatments
• Effective against a range of Influenza strains, promising broad-spectrum antiviral capabilities

Problems Addressed

• Drug resistance in Influenza A due to high mutation rates
• Limited efficacy of existing antiviral treatments against certain viral strains
• Need for antiviral agents with lower cytotoxicity

Market Applications

• Development of new antiviral drugs for Influenza A, including drug-resistant strains
• Potential expansion to treat other types of Influenza viruses (B and C)
• Use in creating combination therapies to enhance efficacy and reduce resistance

Additional Information

Technology ID: 2014-45
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 06 May, 2025